TScan Therapeutics sets separation terms for outgoing CFO and CMO
The company's Form 8-K, with earliest event reported September 24, 2026, details severance terms for Jason Amello and Chrystal Louis.
SEC filing
Latest
5 stories
Yesterday
Wednesday, September 2
TScan cuts 75% of staff, pauses ALLOHA-2 to focus on in vivo solid tumor program
The company also disclosed a Nasdaq bid-price deficiency notice and reported that all 13 tracked patients in ALLOHA Cohort C show complete donor chimerism.
SEC filing
Tuesday, August 18
Amgen terminates Crohn's disease collaboration with TScan Therapeutics
Amgen notified TScan on August 12, 2026 that it is exiting their research agreement, effective November 10, 2026.
SEC filing
Wednesday, August 12
TScan doses first patient in Phase 3 heme trial, cites Cohort C manufacturing data
TScan Therapeutics reports first patient dosed in the ALLOHA-2 Phase 3 trial and shares Cohort C data supporting its commercial-ready manufacturing process, with cash into Q2 2027.
SEC filing